<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005647.pub2" GROUP_ID="HIV" ID="444205111516120353" MERGED_FROM="" MODIFIED="2011-09-06 01:11:19 +0200" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-09-05 15:59:43 -0700" NOTES_MODIFIED_BY="Tara Horvath" REVIEW_NO="MD04" REVMAN_SUB_VERSION="5.1.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2011-09-06 01:11:19 +0200" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings</TITLE>
<CONTACT MODIFIED="2011-09-06 01:11:19 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="9B0B397982E26AA201E6E48BD3864E8C" ROLE="AUTHOR"><PREFIX>Dr.</PREFIX><FIRST_NAME>Derek</FIRST_NAME><LAST_NAME>Sloan</LAST_NAME><POSITION>Medical Officer</POSITION><EMAIL_1>D.J.Sloan@liverpool.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>Hlabisa hospital</ORGANISATION><ADDRESS_1>Private Bag x5001</ADDRESS_1><CITY>Hlabisa</CITY><ZIP>3937</ZIP><REGION>KwaZulu / Natal</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 35 838 1003</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-09-06 01:11:19 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="9B0B397982E26AA201E6E48BD3864E8C" ROLE="AUTHOR"><PREFIX>Dr.</PREFIX><FIRST_NAME>Derek</FIRST_NAME><LAST_NAME>Sloan</LAST_NAME><POSITION>Medical Officer</POSITION><EMAIL_1>D.J.Sloan@liverpool.ac.uk</EMAIL_1><ADDRESS><ORGANISATION>Hlabisa hospital</ORGANISATION><ADDRESS_1>Private Bag x5001</ADDRESS_1><CITY>Hlabisa</CITY><ZIP>3937</ZIP><REGION>KwaZulu / Natal</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 35 838 1003</PHONE_1></ADDRESS></PERSON><PERSON ID="9B0B3C6782E26AA201E6E48BCE29E359" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sipho</FIRST_NAME><LAST_NAME>Dlamini</LAST_NAME><EMAIL_1>sdlamini@polkadot.co.za</EMAIL_1><ADDRESS><ORGANISATION>Hlabisa Hospital</ORGANISATION><CITY>Hlabisa</CITY><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 358381003</PHONE_1></ADDRESS></PERSON><PERSON ID="18550" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Navin</FIRST_NAME><LAST_NAME>Paul</LAST_NAME><EMAIL_1>navinpaul@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine and Infectious Diseases</DEPARTMENT><ORGANISATION>Christian Medical College</ORGANISATION><CITY>Vellore</CITY><ZIP>632004</ZIP><REGION>Tamil Nadu</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 416 3111888</PHONE_1></ADDRESS></PERSON><PERSON ID="14081" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Martin</FIRST_NAME><LAST_NAME>Dedicoat</LAST_NAME><POSITION>Consultant Infectious Disease Physician</POSITION><EMAIL_1>mdedicoat@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Infection</DEPARTMENT><ORGANISATION>Birmingham Heartlands Hospital</ORGANISATION><ADDRESS_1>Bordesley Green East</ADDRESS_1><CITY>Birmingham</CITY><ZIP>B9 5SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 121 424 2357</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-09-05 15:56:59 -0700" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Minor update: 12/08/08&lt;/p&gt;" NOTES_MODIFIED="2011-09-05 15:56:59 -0700" NOTES_MODIFIED_BY="Tara Horvath">
<UP_TO_DATE>
<DATE DAY="31" MONTH="7" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="7" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="8" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2011-09-05 15:58:48 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-09-05 15:58:48 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="5" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Minor amendment to title of plain language summary</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-09-05 15:58:18 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-09-05 15:58:18 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="31" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-05 15:59:43 -0700" MODIFIED_BY="Tara Horvath">
<SUMMARY MODIFIED="2011-09-05 15:59:43 -0700" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2011-09-05 15:59:43 -0700" MODIFIED_BY="Tara Horvath">Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-12 17:52:52 -0700" MODIFIED_BY="Tara Horvath">
<P>Despite the advent and increasingly wide availability of antiretroviral therapy for people with HIV/AIDS, cryptococcal meningitis remains a significant cause of death and illness amongst individuals with HIV infection in resource-limited settings (poor countries). The ideal way to manage cryptococcal meningitis remains unclear. The main aim of this review was to determine the best treatment for cryptococcal meningitis in resource-limited settings. In these settings, usually only Amphotericin and fluconazole are available. The authors didn't find any suitable studies that compared these two drugs. Because Flucytosine, which works well with Amphotericin, is often not available in poor countries, policy makers and government officials should consider using this drug for HIV treatment programmes. Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most effective use of medications that are available in these settings.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-12 17:42:29 -0700" MODIFIED_BY="Tara Horvath">
<ABS_BACKGROUND MODIFIED="2008-08-12 17:37:22 -0700" MODIFIED_BY="Tara Horvath">
<P>Despite the advent and increasingly wide availability of antiretroviral therapy, cryptococcal meningitis (CM) remains a significant cause of mortality and morbidity amongst individuals with HIV infection in resource-limited settings. The ideal management of CM remains unclear. The aim of this review is to assess the evidence for deciding on which antifungal regimen to use as well as other modalities of management to utilise especially resource poor settings in order to achieve the best possible outcome and enable an individual with CM to survive their acute illness and benefit from antiretroviral therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the most effective initial and consolidation treatment strategy for CM in HIV infected adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-12 17:35:02 -0700" MODIFIED_BY="Tara Horvath">
<P>The Cochrane HIV/AIDS group search strategy was used. Key words in the search included, meningitis, cryptococcus neoformans, treatment, trial, human immunodeficiency virus, acquired immunodeficiency syndrome, antifungal agents, amphotericin, flucytosine, fluconazole, azole, lumbar puncture, cerebrospinal fluid (CSF) pressure and acetazolamide.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised of HIV-infected adults with a first episode of CM diagnosed on CSF examination, by India ink staining, CSF culture or cryptococcal antigen testing.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted using standardised forms and analysed using Rev Man 4.2.7 software.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-12 17:41:12 -0700" MODIFIED_BY="Tara Horvath">
<P>Six studies are included in the review. Five of the studies compared antifungal treatments and one study addressed lowering intracranial pressure. This study was stopped early due to excess adverse effects. The results of the other five studies as summarised as follows.</P>
<P>Mayanja-Kizza 1998 compared fluconazole to fluconazole with 5 flucytosine. The dose of fluconazole used 200mg initially is lower than the recommended initial dose of 400mg. No survival advantage was found with the use of 5 flucytosine in addition to fluconazole.</P>
<P>Two studies Brouwer 2004 and van der Horst 1997 compared Amphotericin (AmB) to AmB with 5 flucytosine. Both drugs were given at currently recommended doses for 2 weeks. No survival difference was found at 14 days or at 10 weeks (only recorded in Brouwer 2004). There were significantly more patients with sterile CSF cultures at 14 days in the group that received AmB with flucytosine.</P>
<P>Brouwer 2004 compared AmB given alone to AmB given with flucytosine and fluconazole alone or in combination. This was a small study and no differences in mortality were noted between the groups.</P>
<P>Bicanic 2008 compared high to standard dose AmB both with flucytosine. There was no difference in mortality between the two groups or adverse events.</P>
<P>Leenders 1997 compared standard AmB to liposomal AmB. There was no difference in death rates between the two groups. But there were significantly fewer side effects in the group treated with liposomal AmB.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-12 17:42:29 -0700" MODIFIED_BY="Tara Horvath">
<P>The main aim of this review was to determine the best treatment for cryptococcal meningitis in resource-limited settings. In these settings usually only AmB and fluconazole are available. No studies suitable for inclusion in the review were found that compared these two drugs. Therefore we are unable to recommend either treatment as superior to the other. The recommended treatment for CM is a combination of AmB and flucytosine. The optimal dosing of AmB remains unclear. Liposomal AmB is associated with less adverse events than AmB and may be useful in selected patients where resources allow.<BR/>Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most effective use of medications that are available in these settings.<BR/>Flucytosine in combination with AmB leads to faster and increased sterilisation of CSF compared to using AmB alone. As Flucytosine is often not available in developing countries, policy makers and national departments of heath should consider procuring this drug for HIV treatment programmes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-12 17:36:31 -0700" MODIFIED_BY="Tara Horvath">
<BACKGROUND MODIFIED="2008-08-12 17:35:02 -0700" MODIFIED_BY="Tara Horvath">
<P>Cryptococcal meningitis (CM) was first described in 1905. It is an infection of the brain parenchyma and sub-arachnoid space by the encapsulated saprophytic yeast organism <I>Cryptococcus neoformans</I>, of which there are three subtypes - var gatti, var neoformans and var grubbi(<LINK REF="REF-Lee-1996" TYPE="REFERENCE">Lee 1996</LINK>). Before the global human immunodeficiency virus (HIV) pandemic the main pathogenic strain was <I>C. neoformans var gatti</I>, which is a rare cause of meningitis in immunocompetent individuals in several tropical countries.</P>
<P>Over the last twenty years, HIV has created a large and severely immunocompromised population to whom <I>C.neoformans </I>is a dangerous opportunistic infection. The major burden of disease is in South-East Asia and the African sub-continent. During the 1990's CM was the leading reported cause of adult meningitis in parts of Africa (<LINK REF="REF-Maher-1994" TYPE="REFERENCE">Maher 1994</LINK>, <LINK REF="REF-Moosa-1997" TYPE="REFERENCE">Moosa 1997</LINK>, <LINK REF="REF-Mwaba-2001" TYPE="REFERENCE">Mwaba 2001</LINK>), and 10-30% of AIDS deaths are attributed to the disease (<LINK REF="REF-French-2002" TYPE="REFERENCE">French 2002</LINK>, <LINK REF="REF-Bicanic-2005" TYPE="REFERENCE">Bicanic 2005</LINK>, <LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>). This makes it the second leading cause of death in HIV-infected individuals in Africa after tuberculosis. The majority of these patients are infected with sub-type <I>C. neoformans var grubbi </I>(<LINK REF="REF-Casadevall-2001" TYPE="REFERENCE">Casadevall 2001</LINK>) and infection predominantly occurs in patients with a CD4 counts of less than 100x10<SUP>6</SUP> cells/l (<LINK REF="REF-French-2002" TYPE="REFERENCE">French 2002</LINK>, <LINK REF="REF-Saag-2000" TYPE="REFERENCE">Saag 2000</LINK>). CM is classified as a World Health Organisation HIV / AIDS stage 4 disease.</P>
<P>Over 75% of patients with CM present with headache(<LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>), usually evolving over 2-4 weeks. Fever, nausea, vomiting and seizures are common, but neck stiffness and classical signs of meningism are seen in less than 25% of cases; confusion or behaviour change may be the only sign of infection (<LINK REF="REF-French-2002" TYPE="REFERENCE">French 2002</LINK>, <LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>). Sub-acute dementia can develop, which is reversible with treatment. Space occupying lesions such as cryptococcomas, sub-dural effusions and spinal cord granulomas are occasionally seen and present with focal neurological signs. Visual impairment can occur and blindness is a long-term complication of infection in some immunocompetent patients(Seaton 1997 (a), Seaton 1997 (b)). CM reduces the absorption of cerebrospinal fluid (CSF) leading to raised intracranial pressure (ICP). High ICP is responsible for many of the signs, symptoms and sequelae of CM.</P>
<P>Transmission of <I>C. neoformans</I> is usually by inhalation. A symptomatic respiratory illness may occur but this is rare in HIV-infected patients(<LINK REF="REF-Casadevall-2001" TYPE="REFERENCE">Casadevall 2001</LINK>). The skin is commonly involved as a manifestation of disseminated disease. Cutaneous lesions often resemble molluscum contagiosum but a wide spectrum of plaques and papules have been reported, especially in the immunocompromised population.</P>
<P>Diagnosing CM requires the examination of CSF. Indian Ink staining is the cheapest technique and is relatively easy to perform in developing countries. It has 75% sensitivity on a centrifuged sample(<LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>). A more reliable but expensive test is Cryptococcal antigen detection, which has 99% sensitivity in subjects with titres &gt; 1:2048 (<LINK REF="REF-Van-der-Horst-1997" TYPE="REFERENCE">Van der Horst 1997</LINK>). Fungal culture has a sensitivity of 90%. Microscopic and biochemical features of positive CSF analysis may include a moderate mononuclear leucocytosis, mildly elevated protein and slightly low CSF/blood glucose ratio. These parameters may be normal in 17% of HIV patients with known cryptococcal disease (<LINK REF="REF-Moosa-1997" TYPE="REFERENCE">Moosa 1997</LINK>). Computer tomography brain imaging is of limited supportive diagnostic value as the scan is normal in 50% of proven cases. It can be justified in some cases, however, to exclude mass lesions and other HIV-related pathology (e.g. toxoplasmosis, CNS lymphoma).</P>
<P>HIV associated CM carries a high mortality even when treated appropriately, a study from Thailand reported 43% mortality in patients treated in a tertiary facility, with the majority of the deaths occurring in the first two weeks of therapy (<LINK REF="REF-Imwidthaya-2000" TYPE="REFERENCE">Imwidthaya 2000</LINK>). Three main groups of anti-fungal drugs are used in treatment, amphotericin B (AmB), flucytosine and the azoles. Drug toxicity has been found to be a problem and is reported in up to 60% of patients (<LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>).</P>
<P>AmB, the traditional mainstay of therapy, can be given intravenously, or, rarely, intrathecally, but it has poor oral bioavailability. Although actively fungicidal, it is associated with significant nephrotoxicity. This can be reduced by giving intravenous normal saline pre-medication. Liposomal amphotericin preparations are associated with fewer side effects but are very expensive not available in resource poor settings.</P>
<P>Intra-venous or oral flucytosine displays synergy with AmB. It cannot be used as monotherapy because of rapidly developing drug resistance and significant gastro-intestinal side effects may develop (<LINK REF="REF-Saag-2000" TYPE="REFERENCE">Saag 2000</LINK>, <LINK REF="REF-Graybill-1997" TYPE="REFERENCE">Graybill 1997</LINK>). Drug levels or haematological markers need to be monitored.</P>
<P>The azole compounds (e.g. fluconazole, itraconazole, ketoconazole) were introduced in the 1980s as effective, well tolerated oral and intravenous anti-fungals. Their action against cryptococcal disease has been well described.</P>
<P>Most modern treatment protocols for CM involve combinations of the above drugs. The Infectious Diseases Society of America recommends a 3 step treatment approach - induction (2 weeks of AmB 0.7-1mg/kg/day plus flucytosine 100mg/kg/day) followed by consolidation (8 weeks of fluconazole 400mg/day) and then maintenance (fluconazole 200mg/day for life)(<LINK REF="REF-Saag-2000" TYPE="REFERENCE">Saag 2000</LINK>) but some commentators have questioned the scientific evidence behind this(<LINK REF="REF-Day-2004" TYPE="REFERENCE">Day 2004</LINK>).Other proposed regimes include prolonged courses of AmB and flucytosine, fluconazole and flucytosine dual therapy and the use of AmB alone. In much of the developing world fluconazole is the only drug available, via a donation programme and azole based monotherapy is widely used. A number of these regimes are based on anecdotal reports of open-label phase II clinical trials and the rationale for their use has never been rigorously reviewed.</P>
<P>Raised ICP, is common in CM occurring in more than 50% of patients(<LINK REF="REF-Graybill-1997" TYPE="REFERENCE">Graybill 1997</LINK>). Raised ICP during the first 2 weeks of treatment is associated with a poor clinical response and careful management of ICP is thought to reduce mortality and long term sequelae. Proposed mechanisms to reduce ICP include repeated lumbar puncture, drain insertion and ventriculo-peritoneal shunting(<LINK REF="REF-Denning-1991" TYPE="REFERENCE">Denning 1991</LINK>). Mannitol, acetazolamide and corticosteroids have also been tried, but the effects of these interventions are, at best, unproven.</P>
<P>Initial antifungal treatment rarely eradicates <I>C.neoformans</I> in HIV infected patients but symptoms may improve and control of infection is obtainable with secondary prophylaxis. With the advent of antiretroviral therapy this picture may change with patients that are initially treated with antifungal agents being established on antiretroviral therapy and no longer needing secondary prophylaxis as their immune system improves (<LINK REF="REF-Vibhagool-2003" TYPE="REFERENCE">Vibhagool 2003</LINK>). Combination antiretroviral therapy (ART) is becoming increasingly available in the developing world, many patients in these setting still present with a major opportunistic infection such as CM having not known they were HIV infected. Defining effective evidence based protocols for treatment of CM is important in these patients if they are to benefit from subsequent ART. The timing of initiating ART after acute CM has not been well studied.</P>
<P>The mainstay of treatment for CM in the developing world is fluconazole, which in many cases is the only drug available. The aim of this review will be to look at trials comparing the current gold standard of treatment AmB (often with flucytosine) to fluconazole. Liposomal and standard AmB will be compared, although liposomal AmB is usually not available outside well resourced countries and centres. Also combinations of treatment will be compared and interventions to manage raised ICP.</P>
<P>This review will not look at primary or secondary prophylaxis against cryptococcal infection.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<P>To determine the most effective initial and consolidation treatment strategy for CM in HIV infected adults with an emphasis on resource-limited countries.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<SELECTION_CRITERIA MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<CRIT_STUDIES>
<P>Randomised controlled blinded and unblinded trials</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>HIV-infected adults (Aged &gt;18) with a first episode of CM diagnosed on CSF examination, by India ink staining, CSF culture or cryptococcal antigen testing.<BR/>Acute CM will be defined as a first episode of CM, for which no treatment has been given prior to study entry and which has been diagnosed no longer than two weeks before commencing therapy. Studies including patients receiving antiretroviral therapy were allowed and are commented on in the results and discussion section.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<P>1. Antifungal agents that may be available in resource-limited and other settings (AmB, liposomal AmB, flucytosine and fluconazole) given alone or in combination for the initial treatment and consolidation treatment of acute CM.<BR/>2. Drugs and procedures used to reduce raised ICP in patients with acute CM.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary outcomes</P>
<P>1. Proportion of patients alive two weeks after commencing therapy.<BR/>2. Proportion of patients alive at the end of the follow up period.<BR/>2. Major adverse events secondary to treatment.</P>
<P>Secondary outcomes</P>
<P>1. Proportion of patients with sterile CSF after two weeks of therapy<BR/>2. Proportion of patients who have symptomatic improvement after two weeks of therapy</P>
<P>
<B>Exclusion criteria</B>
</P>
<P>Studies were excluded if the treatment and control groups were not well matched, if retreatment patients were included (as this may affect the organisms sensitivity to the drug under test), if intention to treat analysis was not used, if there was a large loss to follow up or if the methodological quality of the study was felt to be poor.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-12 17:35:02 -0700" MODIFIED_BY="Tara Horvath">
<P>See: Cochrane HIV/AIDS Group search strategy</P>
<P>The following databases were searched: MEDLINE, EMBASE, AIDSLINE, AIDSTRIALS, AIDSDRUGS, CINAHL, LILACS, Database of Abstracts of Reviews of Effectiveness (DARE), the Cochrane HIV/AIDS Group register, and the Cochrane Controlled Trials Register (CENTRAL/CCTR) from the date the database started or from 1980 which ever is later. Abstracts were reviewed from the relevant conferences. Reference lists of relevant articles were hand searched. The searches were completed in July 2008. Unpublished data were not included. Journals in languages other than English were included in the searches if they were indexed in the databases used.</P>
<P>Key words used included: Meningitis, cryptococcus neoformans, treatment, trial, human immunodeficiency virus, acquired immunodeficiency syndrome, antifungal agents, amphotericin, flucytosine, fluconazole, azole, lumber puncture, cerebrospinal fluid pressure and acetazolamide,</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Trials identified by the search were assessed for inclusion in the review. Abstracts of all studies identified were screened by the reviewers. Those felt to meet the criteria for inclusion were reviewed by the reviewers in full. Where there was a conflict between the reviewers as to the suitability of a study to be reviewed this was resolved by discussion or the involvement of a third party (a member of the Cochrane HIV AIDS group). Identified studies were reviewed by the reviewers as to their methodological quality which was graded as A - adequate, B-unclear, C-inadequate and D-not done. The assessment of methodological quality was based on quality of randomisation, allocation concealment, blinding, baseline characteristics of patients, use of intention to treat analysis and completeness of follow-up.</P>
<P>Data was extracted from the selected studies by the reviewers using a standard data extraction form.</P>
<P>Summary ratio measures between trials (odds ratios, relative risks with 95% confidence intervals), were calculated where appropriate using Cochrane REV Man software. Heterogeneity between trials was tested.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-12 17:36:31 -0700" MODIFIED_BY="Tara Horvath">
<STUDY_DESCRIPTION>
<P>Six studies were found that meet the inclusion criteria for the review and were felt to be of sufficient quality to be included. The studies are described below divided into groups by the type of intervention tested. A list of excluded studies with the reason for exclusion is given in the table "Characteristics of excluded studies."</P>
<P>
<B>Studies looking at methods to treat raised intracranial pressure.</B>
</P>
<P>One study <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> was found that looked at treating raised ICP. In this study conducted between 1998 and 2000, 22 adult Thai patients were randomised to receive either acetazolamide (dose adjusted for weight and serum creatinine) or placebo in addition to AmB (1mg/kg) for 14 days. Eligible patients had CM confirmed on Indian Ink staining, headache, GCS&gt;11/15 and CSF opening pressure &gt;200mm/H2O. Exclusion criteria were; weight &lt;35kg, renal or electrolyte disturbance, pregnancy or breast feeding, hypersensitivity to sulphonamides, contraindications for acetazolamide therapy, systolic blood pressure &lt;100mm Hg, a known intracerebral lesion or any infection apart from cryptococcosis and HIV. Lumbar puncture and blood tests were performed on days 2, 4, 7 and 14 after commencement of the acetazolamide/ placebo regime. Primary outcome measures were CSF opening pressure, headache severity and serum potassium and bicarbonate levels at 14 days. 21/22 recruited patients were HIV positive. 10 received placebo and 12 received acetazolamide. 2 additional patients were enrolled in the study but had to be withdrawn as they were underweight.</P>
<P>
<B>Studies comparing different antifungal drugs.</B>
</P>
<P>Five other studies were included. <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB to AmB and flucytosine to AmB, flucytosine and fluconazole. <LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> compared fluconazole to fluconazole and flucytosine, <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> compared AmB to AmB and flucytosine, <LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK> compared standard dose Amb and flucytosine to high dose AmB and flucytosine and <LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> compared liposomal AmB to standard AmB.</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> carried out their study in Thailand. Between May and December 2002, 64 HIV positive adult patients with a first episode of culture positive cryptococcal meningitis were randomised to receive one of four treatments for 14 days: intravenous AmB (0.7mg/kg/day), AmB plus oral flucytosine (100mg/kg/day), AmB plus oral fluconazole (400mg/day) or triple therapy with AmB, flucytosine and fluconazole. Unless contraindicated, 1l 0.9% NaCl was administered intravenously to patients before every AmB infusion to reduce nephrotoxicity. After 2 weeks, all patients were treated with oral fluconazole 400mg daily for 8 weeks, and 200mg daily thereafter. Exclusion criteria were ALT more than five times the upper limit of normal, neutrophil count &lt;500x106/l, platelet count &lt;50,000x106/l, pregnancy or previous adverse reaction to study drugs.</P>
<P>Lumbar puncture (LP) was performed on days 3, 7 and 14 of the study. Additional LPs were done as required on patients with high CSF pressures. Semi-quantitative cultures were done on CSF samples at each time point. This allowed the rate of reduction in the number of colony forming units (CFUs) to be calculated for each patient. The mean rate of fall in CSF log CFU counts was used as a marker of early fungicidal activity (EFA) in each study arm.</P>
<P>16 patients were treated with each of these regimes; AmB alone, AmB plus fluconazole (AmB+F) and triple therapy (AmB+5TC+F). Although 16 patients were randomised to receive AmB plus flucytosine (AmB+5TC) only 15 patients actually participated in this study arm as one patient turned out to be HIV negative. Follow-up of all participants who received study drugs was done at an established HIV clinic and was complete to 10 weeks. </P>
<P>
<LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> carried out their study in Uganda. Between January 1994 and May 1994, 58 HIV positive adults were randomised to receive primary therapy with either oral fluconazole (400mg od on Day 1 then 200mg daily for 2 months) or oral fluconazole plus flucytosine (150mg/kg/day in 3 split doses for 14 days). All patients who responded to primary therapy were continued on maintenance therapy with fluconazole at a dose of 200mg three times per week for 4 more months.</P>
<P>Eligible patients all had positive CSF cultures for <I>C.neoformans </I>and either a positive India Ink test or cryptococcal antigen test by latex agglutination. Pregnant and comatose patients were excluded from the study. 5 patients were diagnosed with tuberculosis had anti-tuberculous therapy administered. No adjustment of fluconazole dose was made during co-prescription of rifampicin. </P>
<P>30 patients received combination therapy, whilst 28 patients received fluconazole alone. Clinical assessments were done weekly for the first 2 months and every two weeks there after. Patients were asked to grade their headache as none, mild, moderate or severe at each review. Repeat lumbar puncture was done at 2 months and 6 months of therapy. Outcomes measured were survival, CSF sterilisation, clinical success (improvement or resolution of headache) and occurrence of adverse events. </P>
<P>
<LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> carried out their study in the United States. The study had two steps. Step One: Between October 1991 and August 1994, 381 HIV positive adult patients were randomised to receive two weeks of AmB 0.7mg/kg daily along with either flucytosine 100mg/kg/day in four divided doses or placebo. Patients were eligible if they presented with a first episode of culture-proven CM and no concurrent opportunistic infections. Patients were excluded if they had been pre-treated with anti-fungals or were co-prescribed agents (including rifampicin) which affected the absorption or metabolism of azole drugs. Comatose patients were also excluded, as were pregnant women, and those with haematologic, renal and hepatic dysfunction. Outcomes measured at 2 weeks were clinical success (fever, headache and meningism improved or no worse) and mycological success (sterile CSF fungal culture). 202 patients received AmB and flucytosine, whilst 179 received AmB alone.</P>
<P>Step Two: At two weeks all patients who were clinically stable with no hepatic dysfunction were randomised to receive oral fluconazole (800mg daily for two days, then 400mg daily for eight weeks) or oral itraconazole (600mg daily for three days, then 300mg daily for eight weeks). Outcomes measured after this time were clinical success (absence of fever, headache and meningism) and mycological success (sterile CSF fungal culture). 75 patients dropped out before this part of the study due to withdrawal of consent (21 patients), death (19 patients), clinical deterioration (11 patients), inability to take oral medications (1 patient), adverse drug events (11 patients), co-prescription of prohibited drugs (7 patients) concurrent opportunistic infections (4 patients) and inadequate total dose of amphotericin B(1 patient). 151 patients received fluconazole and 155 received itraconazole. Due to the large drop out rate this second portion of the study is not included in the analysis below.</P>
<P>
<LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK> carried out their study in Cape Town, South Africa between May 2005 and June 2006. Sixty four HIV infected patients with culture proven <I>c.neoformans </I>meningitis were randomised to receive either AmB 0.7mg/Kg daily (standard dose AmB) with flucytosine 0.25mg/Kg four times a day for two weeks or AmB 1 mg/Kg daily (high dose AmB) with flucytosine 0.25mg/Kg four times a day for two weeks. This initial treatment was followed by fluconazole 400mg daily for a month then fluconazole 200mg daily afterwards. <BR/>Amb infusion was preceded by infusion of 1L of normal saline to reduce nephrotoxicity, electrolytes were supplemented as necessary. Patients developing renal failure where switched from AmB to fluconazole. Lumbar punctures were performed on days 3, 7 and 14 of treatment. Additional lumbar punctures were done in patients with raised ICP or headache. </P>
<P>Eligible patients had to be HIV infected, over 18 years of age, <I>c.neoformans </I>culture positive in their CSF and have a first episode of CM. Patients were excluded if they were pregnant or lactating, if they were taking ARVs, if they had experienced a serious reaction to AmB or flucytosine, had a platelet count under 50 cells/mm<SUP>3 </SUP>, neutrophil count &lt;0.5 cell / mL or an alanine transaminase level greater than five times normal. Patients with reduced level of consciousness were included in the study if a relative was available to give consent. Including these patients meant the investigators were including very sick patients not normally involved in CM trials which is highly commendable as these type of patients commonly present in clinical practice. </P>
<P>Sixty four patients were randomised, 30 received AmB 0.7mg/Kg with flucytosine 0.25mg/Kg and 34 received AmB 1 mg/Kg with flucytosine 0.25mg/Kg. Patients were followed up for one year. Antiretroviral therapy was commenced after 4 weeks of antifungal treatment. </P>
<P>The primary outcome measure was the mean rate of decrease of <I>c.neoformans </I>colony forming units in the CSF, secondary outcome measures were adverse events related to treatment namely anaemia and renal failure, mortality at 2 weeks, 10 weeks and long term survival. </P>
<P>
<LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> conducted their study in the Netherlands and Australia between June 1992 and June 1995. 28 HIV infected patients with culture proven CM were randomised to either 21 days of AmB 0.7mg/Kg daily or liposomal AmB (AmBisome) 4mg/Kg daily for 21 days. Both treatments were followed by 7 weeks of fluconazole 400mg daily then fluconazole 200mg daily indefinitely. Patients were prehydrated with normal saline prior to AmB infusions. Lumbar punctures were performed on days 7, 14 and 21, also after 10 weeks. </P>
<P>Eligible patients had to be aged over 18, give informed consent, have a first episode of CM and have culture proven <I>C.neoformans </I>infection. Exclusion criteria are not clearly stated. </P>
<P>28 patients were randomised, 13 received AmB and 15 liposomal AmB. Patients were followed up for six months. Combination ART was not available at the time of this trial. </P>
<P>The outcome measures were mortality, toxicity and adverse events leading to discontinuation of therapy.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The quality of the trials was assessed by the reviewers independently. The assessment was based on the quality of allocation concealment, blinding, baseline characteristics of patients, use of intention to treat analysis and completeness of follow-up. They are graded A - adequate, B - unclear, C - inadequate, D - not done.</P>
<P>
<B>Quality of allocation concealment:</B>
</P>
<P>The study by <LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK>, <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK>, <LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> and <LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> used sealed envelopes for treatment allocation and were graded A. In the other three studies <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK>
<B> </B>and <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> allocation concealment was unclear therefore these studies were graded B. </P>
<P>
<B>Blinding:</B>
</P>
<P>The study by <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> was double blind and graded A. The study by <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> had two phases the first phase was unblinded and the second phase was double blind therefore the study was graded D/A. The other three studies <LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK>, <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK>, <LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> and <LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> were unblinded and graded D. <B>
<BR/>
</B>
</P>
<P>
<B>Baseline characteristics of patients:</B>
</P>
<P>In all Six studies attempts were made to carefully match patients in all groups for baseline characteristics. All studies were graded A.<BR/>
<B>
<BR/>Use of intention to treat analysis:</B>
</P>
<P>All Six trials used intention to treat analysis and were graded A. <B>
<BR/>
</B>
<BR/>
<B>Completeness of follow-up:<BR/>
</B>
<BR/>Loss to follow up of less then 5% of the total number of patients enrolled was reported in <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> and <LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK>. <LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK> reported 1/64 patients lost to follow up at 10 weeks and 3/64 at 1 year. These three studies were graded A. <LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> reported 8/58 patients lost to follow up, <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> reported 12/24, these trials were graded C. <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> reported 21/306 patients were lost to follow up in stage 2 of their study, this trial was graded C.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-12 17:36:31 -0700" MODIFIED_BY="Tara Horvath">
<P>
<B>Acetazolamide vs placebo</B>
</P>
<P>Only one study addressed treating raised intracranial pressure, <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK>. This study used acetazolamide. No studies of repeated lumbar puncture were found. The study by <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> was terminated early by the safety monitoring committee due to the observation of excess deaths 2/12 vs 0/10 relative risk (RR) 4.23 95% confidence interval (95% CI) 0.23 to 79.1 and excess serious adverse events 5/12 vs 0/10 RR 9.31 95% CI 0.58 to 150.25 in the group of patients receiving acetazolamide. Although these excess events did not reach statistical significance in this small study, acetazolamide can not be recommended for the management of increased intracranial pressure. <B>
<BR/>
</B>
<BR/>
<B>Fluconazole and flucytosine vs fluconazole</B>
</P>
<P>
<LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> compared fluconazole to fluconazole and flucytosine. The dose of fluconazole used 200mg daily is lower than the currently recommended dose of 400mg daily. Flucytosine was given at a dose of 150mg/kg daily. There was no difference in death rate at two weeks 4/25 Vs 10/25 RR 0.4 95% CI 0.14 to 1.11 or at six months 17/25 Vs 22/25 RR0.77 95%CI 0.57 to 1.05. Also there was no difference in number of patients with sterile CSF at 2 months after treatment 4/8 Vs 12/15 RR 0.4 95%CI 0.11 - 1.36. There were no major adverse events in either group.</P>
<P>
<B>AmB vs AmB and flucytosine</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> and <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> compared AmB 0.7mg/kg daily to AmB 0.7mg/kg daily with flucytosine 100mg/kg per day. The studies were analysed together for the outcomes of death at 14 days and sterility of CSF culture at 14 days. There was no difference in the proportion deaths at 14 days 12/195 Vs 12/217 RR1.1 95%CI 0.51 to 2.4, but there was higher proportion of patients with sterile CSF cultures at 14 days in the group of patients receiving flucytosine 93/195 Vs 128/217 RR0.81 95%CI 0.68 to 0.98. There was no difference in major adverse events between the two treatment arms 5/195 Vs 6/217 RR 0.94 95% CI 0.29 to 3.03.<BR/>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> recorded deaths at 10 weeks there was no difference between the two groups 3/16 Vs 1/16 RR 2.81 95%CI 0.33 to 24.16.<BR/>
<LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> found no difference in symptomatic improvement at 14 days between the two groups 149/179 Vs 157/202 RR 1.07 95%CI 0.97 to 1.18.</P>
<P>
<B>
<BR/>AmB vs AmB, flucytosine and fluconazole</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB to AmB, flucytosine and fluconazole. AmB was given at a dose of 0.7mg/kg daily, flucytosine 100mg/kg daily and fluconazole was given at a dose of 400mg daily. There was no significant difference in the proportion of patients dying at two weeks or ten weeks 2/16 Vs 1/16 RR2.0 95%CI 0.2 to 19.91 and 3/16 Vs 3/16 RR 1.0 95%CI 0.24 to 4.23. There was also no difference in the proportion of patients sterile CSF at 14 days 2/16 Vs 4/16 RR0.5 95%CI 0.11 to 2.35. There were no serious adverse events in either group.</P>
<P>
<B>AmB and flucytosine vs AmB, flucytosine and fluconazole</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB and flucytosine to AmB, flucytosine and fluconazole. There was no difference in death at 14 days or 10 weeks between the groups 1/15 Vs 1/16 RR 1.07 95%CI 0.07 to 15.57 and 1/15 Vs 3/16 RR 1.07 95%CI 0.07 to 15.57. Also there was no difference in the proportion of patients with sterile CSF at 14 days 6/15 Vs 4/16 RR 1.6 95%CI 0.56 to 4.58. There were no serious adverse events in either group.<BR/>
<B>
<BR/>
<BR/>AmB and flucytosine vs AmB and fluconazole</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB and flucytosine to AmB and fluconazole. There was no difference in the proportion of deaths at 14 days or 10 weeks 1/15 Vs 5/16 RR 0.21 95%CI 0.03 to 1.62 and 1/15 Vs 7/16 RR 0.15 95%CI 0.02 to 1.1. Also there was no difference in the amount of patients with sterile CSF at 14 days 6/15 Vs 3/16 RR 2.13 95%CI 0.65 to 7.04. There were no serious adverse events in either group.<BR/>
</P>
<P>
<B>AmB vs AmB and fluconazole</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB to AmB and fluconazole. There was no difference in the proportion deaths at 14 days or 10 weeks 2/16 Vs 5/16 RR 0.4 95%CI 0.09 to 1.77 and 3/16 Vs 7/16 RR 0.43 95% CI 0.13 to 1.37. Also there was no difference in the amount of patients with sterile CSF at 14 days 2/16 Vs 3/16 RR 0.67 95%CI 0.13 to 3.47. There were no serious adverse events in either group.<BR/>
</P>
<P>
<B>AmB and fluconazole vs AmB, flucytosine and fluconazole</B>
</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB and fluconazole to AmB, flucytosine and fluconazole. There was no difference in the proportion deaths at 14 days or 10 weeks 5/16 Vs 1/16 RR 5.0 95%CI 0.66 to 38.15 and 7/16 Vs 3/16 RR 2.33 95%CI 0.73 to 7.45. Also there was no difference in the amount of patients with sterile CSF at 14 days 3/16 Vs 4/16 RR 0.75 95%CI 0.2 to 2.83. There were no serious adverse events in either group.</P>
<P>
<B>Standard dose AmB and Flucytosine Vs high dose AmB and flucytosine. </B>
</P>
<P>
<LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK> compared AmB 0.7mg/Kg with flucytosine 0.25mg/Kg for 2 weeks with AmB 1 mg/Kg with flucytosine 0.25mg/Kg for 2 weeks. There was no difference in the proportion of deaths at 14 days or 10 weeks 1/30 Vs 3/34 RR0.34 95% CI 0.04 - 3.44 and 6/30 Vs 9/34 RR 0.76 95% CI 0.03 - 1.83. The proportion of patients with sterile CSF at 14 days was not different between the two treatment groups 6/29 Vs 7/28 RR 1.13 95% CI 0.43 - 2.94. There was also no major difference in major adverse events defined as side effects of treatment leading the study interventions being terminated 1/30 Vs 5/34 RR 0.23 95% CI 0.03 - 1.83.</P>
<P>
<B>AmB Vs liposomal AmB</B>
</P>
<P>
<LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> compared AmB 0.7mg/Kg daily for 21 days with liposomal AmB 4mg/Kg daily for 21 days. There was no difference in the proportion of patients who had a clinical response after 3 weeks treatment 12/15 in the liposomal AmB group Vs 11/13 in the AmB group RR 0.95 95% CI 0.67 - 1.33. There was no difference in the proportion of deaths at 14 days, 10 weeks or 6 months. At 6 months 2/15 patients who received liposomal AmB had died and 1/13 patients who received AmB RR 1.73 95%CI 0.12 - 59.4.<BR/>Major adverse events were less common in patients who received liposomal AmB 2/15 Vs 9/13 RR 0.19 95% CI 0.05 - 0.74.<BR/>There was no statistically significant difference in the proportion of patients with sterile CSF at 14 days in either group but the trend suggests that liposomal AmB was superior with 10/15 patients having sterile CSF Vs 1/9 in the AmB group RR 6.0 95% CI 0.91 - 39.41.</P>
<P>I<B>n Summary. </B>
</P>
<P>
<LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> compared acetazolamide to placebo for reducing raised ICP. This study was terminated due to safety concerns and therefore acetazolamide can not be recommended for management of raised ICP in CM. <B>
<BR/>
</B>
<BR/>
<LINK REF="STD-Mayanja_x002d_Kizza-1998" TYPE="STUDY">Mayanja-Kizza 1998</LINK> compared fluconazole to fluconazole with 5 flucytosine. The dose of fluconazole used 200mg initially is lower than the recommended initial dose of 400mg. No survival advantage was found with the use of 5 flucytosine in addition to fluconazole.</P>
<P>Two studies <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> and <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> compared AmB to AmB with 5 flucytosine. Both drugs were given at currently recommended doses for 2 weeks. No survival difference was found at 14 days or at 10 weeks (only recorded in <LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK>). There were significantly more patients with sterile CSF cultures at 14 days in the group that received AmB with flucytosine.</P>
<P>
<LINK REF="STD-Brouwer-2004" TYPE="STUDY">Brouwer 2004</LINK> compared AmB given alone to AmB given with flucytosine and fluconazole alone or in combination. This was a small study and no differences in mortality were noted between the groups.</P>
<P>
<LINK REF="STD-Bicanic-2008" TYPE="STUDY">Bicanic 2008</LINK> compared high to standard dose AmB both with flucytosine. There was no difference in mortality between the two groups or adverse events.</P>
<P>
<LINK REF="STD-Leenders-1997" TYPE="STUDY">Leenders 1997</LINK> compared standard to liposomal AmB. There was no difference in death rates between the two groups. But there were significantly fewer side effects in the group treated with liposomal AmB.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<P>Six studies were found that met the inclusion criteria. Five of the studies compared antifungal treatments and one study <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK> addressed lowering intracranial pressure, this study was terminated prematurely by the safety monitoring committee due to concerns over excess mortality in the intervention group who received acetazolamide. Therefore acetazolamide can not be recommended for the management of raised ICP in CM. No studies were found that examined the use of repeated lumbar puncture in the management of raised ICP. A limitation of the studies of antifungal therapy reviewed is that different approaches to controlling raised intracranial pressure were used. It is felt that aggressive management of raised ICP has an important impact on mortality and long term neurological disability <LINK REF="REF-Pappas-2005" TYPE="REFERENCE">Pappas 2005</LINK>; <LINK REF="REF-Saag-2000" TYPE="REFERENCE">Saag 2000</LINK>. This difference in management may have impacted on survival differences between the studies, for example <LINK REF="STD-van-der-Horst-1997" TYPE="STUDY">van der Horst 1997</LINK> used a combination of repeat lumbar punctures and acetazolamide to lower raised ICP, acetazolamide has subsequently been associated with adverse outcomes <LINK REF="STD-Newton-2002" TYPE="STUDY">Newton 2002</LINK>. The method of optimal management of raised ICP remains an important unanswered question that could significantly impact on survival. </P>
<P>The main aim of this review was to determine the best treatment for cryptococcal meningitis with an emphasis on resource-limited settings. In these settings usually only AmB and fluconazole are available. No study suitable for inclusion was found that directly compared AmB to Fluconazole for primary treatment of CM. Therefore we are unable comment or to recommend either treatment as superior to the other. </P>
<P>The addition of flucytosine to AmB increased the proportion of patients with sterile CSF cultures at 14 days but this did not translate into a survival benefit during the follow up period of the studies reviewed. It is not known if over a longer period faster sterilisation of CSF will confer a survival advantage but it may well do so, therefore it is recommended where possible to treat patients with a combination of AmB and flucytosine. High dose AmB did not impact on early mortality even though there was a trend to wards better fungicidal activity. There is insufficient evidence to recommend to recommend high dose AmB over standard dose AmB when combined with flucytosine.</P>
<P>Liposomal AmB was found to be associated with less adverse events compared to standard AmB but the overall outcome as the same. Liposomal AmB in view if its high cost is not available in public facilities in resource-limited settings. But this formulation does have a role where resources are not an issue and especially in patients with co morbidities such as renal impairment.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<IMPLICATIONS_PRACTICE>
<P>No evidence was found to recommend the use of fluconazole in place of AmB as first line therapy for CM. No evidence was found to recommend the frequency of lumbar punctures necessary to control raised ICP. In view of the superior antifungal activity of AmB / flucytosine combination therapy, policy makers in national departments of health should consider making flucytosine available to public HIV treatment programmes in all settings.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-12 17:36:15 -0700" MODIFIED_BY="Tara Horvath">
<P>Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most effective use of medications that are available in these settings. For example the combination of AmB and fluconazole could be compared to AmB alone. Also studies looking at the best time to initiate ART in relation to an acute episode of CM are needed. Optimal dosing of both fluconazole and amphoteracin also needed to be elucidated, namely doses that improve survival without causing excessive toxicity.<BR/>Also ideal management of raised intracranial pressure needs to be determined. A trial looking at various regimens for repeat lumbar puncture to control raised ICP is warranted.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank the Karishma Busgeeth and the South African Cochrane Centre for performing the original searches for this review and ongoing support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None of the reviewers has any potential conflict of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All reviewers contributed equally to the design of the protocol</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bicanic-2008" NAME="Bicanic 2008" YEAR="2008">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, Bekker LG, Jaffar S, Harrison T.</AU>
<TI>High-Dose Amphoteracin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>123-130</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-2004" NAME="Brouwer 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer AE, Rajanuwong A, Chierakul W,Griffin GE, Larsen RA, White NJ.</AU>
<TI>Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>1764 - 1767</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leenders-1997" NAME="Leenders 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leenders ACAP, Reiss P, Portegies P, Clezy K, Hop WCJ, Hoy J, Borleffs JCC, Allworth T, Kauffmann RH, Jones P, Kroon FP, Verbrugh HA, de Marie S.</AU>
<TI>Liposomal amphoteracin B (Ambisome) compared with amphoteracin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.</TI>
<SO>AIDS</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>1463 - 1471</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayanja_x002d_Kizza-1998" NAME="Mayanja-Kizza 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, Izumi T, Ococi-Jungala, Augustine K, Mugerwa R, Nagatake T, Matsumoto K.</AU>
<TI>Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>1362 - 1366</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-2002" NAME="Newton 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton PN, Thai LH, Tip NQ, Short JM, Chierakul W, Rajanuwong A, Pitisuttithum P, Chasombat S, Phonrat B, Maek-A-Nantawat W, Teaunadi R, Lalloo DG, White NJ.</AU>
<TI>A randomised, double blind placebo controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>796 - 772</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Horst-1997" NAME="van der Horst 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderley WG, Dismukes WE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group and the AIDS Clinical Trials Group.</AU>
<TI>Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>15 - 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouwer-2007" NAME="Brouwer 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brouwer AE, van Kan HJM, Johnson E, Rajanuwong A, Peparrukkul P, Wuthiekanun V, Chierakul W, Day N, Harrison TS.</AU>
<TI>Oral versus intravenous flucytosine in patients with human immunodeficiency virus associated cryptococcal meningitis.</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2007</YR>
<VL>51</VL>
<PG>1038 - 1042</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chotmongkol-1997" NAME="Chotmongkol 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chotmongkol V, Sukeepaisarncharoen W, Thavornpitak Y.</AU>
<TI>Comparison of amphoteracin B, flucytosine and itraconazole with amphoteracin B and flucytosine in the treatment of cryptococcal meningitis in AIDS.</TI>
<SO>Journal of the Medical Association of Thailand.</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>7</NO>
<PG>416 - 424</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chotmongkol-2005" NAME="Chotmongkol 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chotmongkol V, Arayawichanont A, Sawanyawisuth K, Thavornpitak Y.</AU>
<TI>Initial treatment of cryptococcal meningitis in AIDS</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>1</NO>
<PG>170 - 173</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Gans-1992" NAME="de Gans 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JKM, van Boxtel CJV, van Ketel RJ, Stam J</AU>
<TI>Itraconazole compared with amphoteracin B plus flucytosine in AIDS patients with cryptococcal meningitis.</TI>
<SO>AIDS</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>185 - 190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larsen-1990" NAME="Larsen 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Larsen RA, Leal MAE, Chan LS.</AU>
<TI>Fluconazole compared with amphoteracin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>113</VL>
<PG>183 - 187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saag-1992" NAME="Saag 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saag MS, Powderly WG, Cloud MS, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group.</AU>
<TI>Comparison of amphoteracin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis.</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<PG>83 - 89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharkey-1996" NAME="Sharkey 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharkey PK , Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Harvard P, Eng RHK, Patterson TF, Pottage JC, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS.</AU>
<TI>Amphoteracin B lipid complex compared with amphoteracin in the treatment of cryptococcal meningitis in patients with AIDS.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>315 - 321</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tansuphaswadikul2006" NAME="Tansuphaswadikul2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tansuphaswadikul S, Maek-a-Nantawar W, Phonrat B, Boonpok L, Getahun A, Pitisuttithum P.</AU>
<TI>Comparison of one week with two week regimens of amphoteracin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients.</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2006</YR>
<VL>89</VL>
<NO>10</NO>
<PG>1677 - 1685</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bicanic-2005" NAME="Bicanic 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bicanic T, Harrison TS</AU>
<TI>Cryptococcal meningitis</TI>
<SO>British Medical Bulletin</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>99-118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casadevall-2001" NAME="Casadevall 2001" TYPE="BOOK">
<AU>Casadevall A, Prefect JR</AU>
<TI>Cryptococcus neoformans</TI>
<SO>American Society for Microbiology Press</SO>
<YR>2001</YR>
<PB>American Society for Microbiology Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-2004" NAME="Day 2004" TYPE="JOURNAL_ARTICLE">
<AU>Day J</AU>
<TI>Cryptococcal meningitis</TI>
<SO>Practicle Neurology</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>274-285</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denning-1991" NAME="Denning 1991" TYPE="JOURNAL_ARTICLE">
<AU>Denning DM, Armstrong RW, Lewis BH, Stevens DA</AU>
<TI>Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91</VL>
<PG>267-272</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2002" NAME="French 2002" TYPE="JOURNAL_ARTICLE">
<AU>French N, Gray K, Waters C, Nakiyingi J, Lugada E, Moore M, Lalloo D, Whitworth JAG, Gilks CF</AU>
<TI>Cryptococcal infection in a cohort of HIV-1 infected Ugandan adults</TI>
<SO>AIDS</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>1031-1038</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graybill-1997" NAME="Graybill 1997" TYPE="CONFERENCE_PROC">
<AU>Graybill JR, Sobel J, Saag M et al</AU>
<TI>Cerebrospinal fluid hypertension in patients with AIDS and cryptococcal meningitis</TI>
<SO>Programme and abstracts 1-153 of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto Canada</SO>
<YR>1997</YR>
<PB>American Society of Microbiology</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imwidthaya-2000" NAME="Imwidthaya 2000" TYPE="JOURNAL_ARTICLE">
<AU>Imwidthaya P, Poungvarin N.</AU>
<TI>Cryptococcosis in AIDS</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2000</YR>
<VL>76</VL>
<PG>85-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1996" NAME="Lee 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lee SC, Dickinson DW, Casadevall A.</AU>
<TI>Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenic implications.</TI>
<SO>Human Pathology</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>839 - 847</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maher-1994" NAME="Maher 1994" TYPE="JOURNAL_ARTICLE">
<AU>Maher D, Mwandumba H</AU>
<TI>Cryptococcal meningitis in Lilongwe and Blantyre, Malawi</TI>
<SO>Journal of Infection</SO>
<YR>1994</YR>
<VL>28</VL>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moosa-1997" NAME="Moosa 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moosa MY, Coovadia YM.</AU>
<TI>Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings and outcome of human immunodeficiency virus (HIV) - positive and HIV negative patients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>131-134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mwaba-2001" NAME="Mwaba 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mwaba P, Mwansa J, Chintu C</AU>
<TI>Clinical presentation, natural history and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions</TI>
<SO>Post Graduate Medicine</SO>
<YR>2001</YR>
<VL>77</VL>
<PG>769-773</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pappas-2005" NAME="Pappas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pappas PG</AU>
<TI>Managing Cryptococcal Meningitis is about Handling the Pressure.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>480 - 482</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saag-2000" NAME="Saag 2000" TYPE="JOURNAL_ARTICLE">
<AU>Saag MS, Graybill RJ, Larsen RA, Pappas PG, Prefect JR, Powderly WG, Sobel JD, Dismukes WE</AU>
<TI>Practicle guidelines for the managment of cryptococcal disease</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>710-718</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seaton-1997-_x0028_a_x0029_" NAME="Seaton 1997 (a)" TYPE="JOURNAL_ARTICLE">
<AU>Seaton RA, Verma N, Naraqi S, Wembri JP, Warrel DA</AU>
<TI>The effects of corticosteroids on visual loss in Cryptococcus neoformans var. gatti meningitis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygeine</SO>
<YR>1997</YR>
<VL>91</VL>
<PG>50-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seaton-1997-_x0028_b_x0029_" NAME="Seaton 1997 (b)" TYPE="JOURNAL_ARTICLE">
<AU>Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA</AU>
<TI>Visual loss in immunocompetent patients with Cryptococcus neoformans var. gatti meningitis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<PG>44-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Horst-1997" NAME="Van der Horst 1997" TYPE="JOURNAL_ARTICLE">
<AU>Van der Horst C, Saag MS, Cloud GA et al</AU>
<TI>Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome</TI>
<SO>New Engand Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vibhagool-2003" NAME="Vibhagool 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tanssuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A</AU>
<TI>Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immuodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>1329-1331</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bicanic-2008">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in South Africa</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphoteracin 0.7mg/Kg and flucytosine Vs Amphoteracin 1mg/Kg and flucytosine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Mycological outcome<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brouwer-2004">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in Thailand</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Amphoteracin B Vs amphoteracin B and flucytosine Vs amphoteracin B and fluconazole Vs amphoteracin B, flucytosine and fluconazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, mycological outcome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Leenders-1997">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in Holland and Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ambisome Vs amphoteracin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Mycological outcome<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mayanja_x002d_Kizza-1998">
<CHAR_METHODS>
<P>Randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in Uganda</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fluconazole and flucytosine Vs fluconazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, headache severity, mycological response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Newton-2002">
<CHAR_METHODS>
<P>Randomised double blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in Thailand</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acetzolamide Vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CSF opening pressure, headache severity, serum potassium and bicarbonate levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-der-Horst-1997">
<CHAR_METHODS>
<P>Randomised double blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>HIV infected adults with cryptococcal meningitis in the USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Step one - amphoteracin B and flucytosine Vs. amphoteracin B. Step 2. Maintainence therapy with fluconazole Vs maintainence therapy with itraconazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, resolution of headache, meningism and fever. Mycological response at 2 weeks and 10 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brouwer-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a substudy of Brouwer 2004.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chotmongkol-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study included retreatment patients, which may have biased the results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chotmongkol-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control and study group not well matched for severity of disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Gans-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Several patients were lost to follow up and several patients were switched from the itraconazole to amphoteracin treatment arm due to deterioration in thier clinical condition. In such a small study this factors may have affected the conclusions reached about treatment efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Larsen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a small study where many patients were excluded before randomisation. Also intention to treat analysis was not used meaning 6/26 patients were excluded from the final analysis. Also the two groups were not well matched for CD4 counts.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saag-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study included 8 patients who were retreatment patients. This may bias the results as the patients may have C.neformans infection that is resistant to the treatments under trail due to previous exposure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharkey-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control and study groups are poorly matched for baseline characteristics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tansuphaswadikul2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Large loss to follow at end of 10 week period. Fifteen patients (50%) lost in group of individuals given 1 week treatment with amphoteracin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bicanic-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brouwer-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leenders-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mayanja_x002d_Kizza-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Newton-2002">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-der-Horst-1997">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Acetzolamide Vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="79.09554041147656" CI_START="0.22630110611680598" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.898151997665993" LOG_CI_START="-0.6453133232911787" LOG_EFFECT_SIZE="0.626419337187407" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.33433324231515715" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.9654225123421243">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" ORDER="177" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Newton-2002" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="150.25345791155186" CI_START="0.5765799822435504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.307692307692308" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="2.1768244755807684" LOG_CI_START="-0.2391404395615415" LOG_EFFECT_SIZE="0.9688420180096133" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.11596071936784384" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001" Z="1.5719561572326035">
<NAME>Serious adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="150.25345791155175" CI_START="0.5765799822435507" EFFECT_SIZE="9.307692307692308" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.176824475580768" LOG_CI_START="-0.23914043956154132" LOG_EFFECT_SIZE="0.9688420180096133" ORDER="178" O_E="0.0" SE="1.4191497503737982" STUDY_ID="STD-Newton-2002" TOTAL_1="12" TOTAL_2="10" VAR="2.0139860139860137" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Fluconzaole and flucytosine Vs fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1075345610261507" CI_START="0.1444650177343063" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.044357287426712286" LOG_CI_START="-0.8402373047707875" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07783265616001285" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.7634023356783417">
<NAME>Death at 2 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1075345610261507" CI_START="0.1444650177343063" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.044357287426712286" LOG_CI_START="-0.8402373047707875" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="179" O_E="0.0" SE="0.5196152422706632" STUDY_ID="STD-Mayanja_x002d_Kizza-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.27" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0487103524670922" CI_START="0.5693730748550665" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7727272727272727" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.020655555214354863" LOG_CI_START="-0.24460307410221951" LOG_EFFECT_SIZE="-0.11197375944393231" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.09798106922902342" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.00000000000001" Z="1.654721177509652">
<NAME>Death at six months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0487103524670922" CI_START="0.5693730748550666" EFFECT_SIZE="0.7727272727272727" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.020655555214354863" LOG_CI_START="-0.24460307410221943" LOG_EFFECT_SIZE="-0.11197375944393231" ORDER="180" O_E="0.0" SE="0.1558142319119475" STUDY_ID="STD-Mayanja_x002d_Kizza-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.024278074866310152" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.0" STUDY_ID="STD-Mayanja_x002d_Kizza-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1470514835944627E-32" CI_END="1.3638600811592863" CI_START="0.11731408684093121" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39999999999999997" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="100.0" I2_Q="100.0" ID="CMP-002.04" LOG_CI_END="0.13476981819631761" LOG_CI_START="-0.9306498355403928" LOG_EFFECT_SIZE="-0.39794000867203766" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.14316271571360806" Q="3.147051483594462E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="8" WEIGHT="100.00000000000001" Z="1.4641143182768688">
<NAME>Sterile CSF culture at 2 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3638600811592863" CI_START="0.11731408684093121" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.13476981819631761" LOG_CI_START="-0.9306498355403928" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="182" O_E="0.0" SE="0.6258327785172862" STUDY_ID="STD-Mayanja_x002d_Kizza-1998" TOTAL_1="15" TOTAL_2="8" VAR="0.3916666666666666" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Amphoteracin Vs fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Death after 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Amphoteracin Vs amphoteracin and flucytosine</NAME>
<DICH_OUTCOME CHI2="0.10965978429521601" CI_END="2.8470361978328365" CI_START="0.5973156563138513" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3040626116325138" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.4543929888958558" LOG_CI_START="-0.22379610175786493" LOG_EFFECT_SIZE="0.11529844356899543" METHOD="MH" NO="1" P_CHI2="0.7405318380659289" P_Q="1.0" P_Z="0.5051400296887008" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="217" WEIGHT="100.0" Z="0.6664241580498654">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.60416152208956" CI_START="0.18896981709311333" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2696101014182621" LOG_CI_START="-0.7236075572907867" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="183" O_E="0.0" SE="1.1708259193122321" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="15" VAR="1.3708333333333333" WEIGHT="9.898353521904328"/>
<DICH_DATA CI_END="2.8536337762182606" CI_START="0.5399876291776999" EFFECT_SIZE="1.241340782122905" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.45539823676287333" LOG_CI_START="-0.267616189512962" LOG_EFFECT_SIZE="0.09389102362495563" ORDER="184" O_E="0.0" SE="0.4247022529735568" STUDY_ID="STD-van-der-Horst-1997" TOTAL_1="179" TOTAL_2="202" VAR="0.18037200368081502" WEIGHT="90.10164647809567"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="24.16320442434011" CI_START="0.3273637101721463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.3831545281082893" LOG_CI_START="-0.48496946586945155" LOG_EFFECT_SIZE="0.4490925311194189" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.34601794662194896" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="0.9423412895048789">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.16320442434011" CI_START="0.3273637101721463" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3831545281082893" LOG_CI_START="-0.48496946586945155" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="185" O_E="0.0" SE="1.0973452814254347" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="15" VAR="1.2041666666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0289016792490697" CI_START="0.2919772466505012" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9404096834264432" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="100.0" ID="CMP-004.03" LOG_CI_END="0.48128517598963355" LOG_CI_START="-0.5346509911514221" LOG_EFFECT_SIZE="-0.02668290758089425" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.9179991799142186" Q="1.351986787663348E-34" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="217" WEIGHT="99.99999999999999" Z="0.1029543775541212">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="186" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0289016792490706" CI_START="0.2919772466505011" EFFECT_SIZE="0.9404096834264432" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.48128517598963366" LOG_CI_START="-0.5346509911514222" LOG_EFFECT_SIZE="-0.02668290758089425" ORDER="187" O_E="0.0" SE="0.5967659335437897" STUDY_ID="STD-van-der-Horst-1997" TOTAL_1="179" TOTAL_2="202" VAR="0.3561295794383908" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.831953680569317" CI_END="0.9768419512724225" CI_START="0.6793300317836661" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8146152919050275" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="128" I2="45.41346702121696" I2_Q="100.0" ID="CMP-004.04" LOG_CI_END="-0.010175697532771628" LOG_CI_START="-0.1679191857189601" LOG_EFFECT_SIZE="-0.08904744162586589" METHOD="MH" NO="4" P_CHI2="0.1758971285888984" P_Q="0.0" P_Z="0.026909353272545684" Q="8.972684404329721E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="217" WEIGHT="100.0" Z="2.212830215801089">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3149318759720083" CI_START="0.07426715542036098" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.11890325346773722" LOG_CI_START="-1.1292032101075493" LOG_EFFECT_SIZE="-0.5051499783199059" ORDER="188" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.5375" WEIGHT="5.125890962702192"/>
<DICH_DATA CI_END="1.0100433632448593" CI_START="0.7014872484525934" EFFECT_SIZE="0.8417437494276032" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="122" LOG_CI_END="0.004340019340758185" LOG_CI_START="-0.1539802191146063" LOG_EFFECT_SIZE="-0.07482009988692405" ORDER="189" O_E="0.0" SE="0.09299809176650077" STUDY_ID="STD-van-der-Horst-1997" TOTAL_1="179" TOTAL_2="202" VAR="0.008648645072210498" WEIGHT="94.87410903729781"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1822676547475752" CI_START="0.9701839839538465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0709888623990322" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="157" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.07271580803506623" LOG_CI_START="-0.01314589909552431" LOG_EFFECT_SIZE="0.029784954469770943" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.1738927552341615" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="202" WEIGHT="100.0" Z="1.3598014759508041">
<NAME>Symptomatic improvement at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1822676547475752" CI_START="0.9701839839538465" EFFECT_SIZE="1.0709888623990322" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="157" LOG_CI_END="0.07271580803506623" LOG_CI_START="-0.01314589909552431" LOG_EFFECT_SIZE="0.029784954469770943" ORDER="190" O_E="0.0" SE="0.050435591790813854" STUDY_ID="STD-van-der-Horst-1997" TOTAL_1="179" TOTAL_2="202" VAR="0.00254374891928961" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Amphoteracin Vs amphoteracin, flycytosine and fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.91371461525375" CI_START="0.20086659256109013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="1.2991522789342274" LOG_CI_START="-0.6970922876062648" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.554441428961691" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.5911179017410079">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.91371461525375" CI_START="0.20086659256109013" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2991522789342274" LOG_CI_START="-0.6970922876062648" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="191" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="1.375" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.231237209631626" CI_START="0.23633749432049936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.6264673732269029" LOG_CI_START="-0.6264673732269029" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.231237209631626" CI_START="0.23633749432049936" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6264673732269029" LOG_CI_START="-0.6264673732269029" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.7359800721939872" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.5416666666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="193" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3545282765375117" CI_START="0.10617838082099462" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.3719039104383159" LOG_CI_START="-0.9739639017662782" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3806118373804923" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.8767695377173651">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3545282765375117" CI_START="0.10617838082099462" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3719039104383159" LOG_CI_START="-0.9739639017662782" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="194" O_E="0.0" SE="0.7905694150420949" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.625" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Amphoteracin and flucytosine Vs amphoteracin, flucytosine and fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.570001590060363" CI_START="0.07307499432139536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.19228865691972" LOG_CI_START="-1.1362312097192329" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9623659989009873" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.04718472844159172">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.570001590060363" CI_START="0.07307499432139536" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19228865691972" LOG_CI_START="-1.1362312097192329" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="195" O_E="0.0" SE="1.3677840960229555" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="1.8708333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.570001590060363" CI_START="0.07307499432139536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.19228865691972" LOG_CI_START="-1.1362312097192329" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9623659989009873" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.04718472844159172">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.570001590060363" CI_START="0.07307499432139536" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19228865691972" LOG_CI_START="-1.1362312097192329" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="196" O_E="0.0" SE="1.3677840960229555" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="1.8708333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="197" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.576420933182969" CI_START="0.5593891028331353" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.6605259634578462" LOG_CI_START="-0.25228599814599656" LOG_EFFECT_SIZE="0.2041199826559248" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.380724982794021" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.8765612883240924">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.576420933182969" CI_START="0.5593891028331353" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6605259634578462" LOG_CI_START="-0.25228599814599656" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="198" O_E="0.0" SE="0.5361902647381804" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="0.2875" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Amphoteracin and flucytosine Vs amphoteracin and fluconazole</NAME>
<DICH_OUTCOME CHI2="4.6042465285273063E-32" CI_END="1.621404018773647" CI_START="0.028068951713548593" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21333333333333337" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.20989124511462143" LOG_CI_START="-1.5517738065861717" LOG_EFFECT_SIZE="-0.6709412807357752" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.13545567675930137" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="99.99999999999999" Z="1.4929293678315467">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6214040187736465" CI_START="0.02806895171354858" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2098912451146213" LOG_CI_START="-1.551773806586172" LOG_EFFECT_SIZE="-0.6709412807357752" ORDER="199" O_E="0.0" SE="1.0348107717516923" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="1.0708333333333333" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0963244427475454" CI_START="0.021179820264094054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.03993909688886238" LOG_CI_START="-1.674077729716889" LOG_EFFECT_SIZE="-0.8170693164140133" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0616751534601751" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.8686239343583517">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0963244427475454" CI_START="0.021179820264094054" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03993909688886238" LOG_CI_START="-1.674077729716889" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="200" O_E="0.0" SE="1.0068219684683466" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="1.0136904761904761" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="201" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.03731751140908" CI_START="0.6467110662170256" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.8474071460738787" LOG_CI_START="-0.1892897075454292" LOG_EFFECT_SIZE="0.32905871926422475" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.21341596062665613" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.2442272517855848">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.03731751140908" CI_START="0.6467110662170256" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8474071460738787" LOG_CI_START="-0.1892897075454292" LOG_EFFECT_SIZE="0.32905871926422475" ORDER="202" O_E="0.0" SE="0.6089608635481704" STUDY_ID="STD-Brouwer-2004" TOTAL_1="15" TOTAL_2="16" VAR="0.37083333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Amphoteracin Vs amphoteracin and fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7681354001622964" CI_START="0.09049080742646387" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.24751551932623395" LOG_CI_START="-1.0433955366703092" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.22690559858469894" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.208368433102705">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7681354001622964" CI_START="0.09049080742646387" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24751551932623395" LOG_CI_START="-1.0433955366703092" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="203" O_E="0.0" SE="0.758287544405155" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.575" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.369167356927866" CI_START="0.13414975784982278" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.13645653633562024" LOG_CI_START="-0.872410106924809" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1527843988746297" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.4297652740176028">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.369167356927866" CI_START="0.13414975784982278" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.13645653633562024" LOG_CI_START="-0.872410106924809" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="204" O_E="0.0" SE="0.592613260221602" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.35119047619047616" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="205" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.469777208882955" CI_START="0.128090196484842" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.5403015900476404" LOG_CI_START="-0.892484108159003" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6299733682847319" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.48176433666728474">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.469777208882954" CI_START="0.12809019648484204" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5403015900476403" LOG_CI_START="-0.8924841081590028" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="206" O_E="0.0" SE="0.8416254115301731" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.7083333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Amphoteracin and fluconazole Vs amphoteracin, flucytosine and fluconazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="38.15175744716649" CI_START="0.6552778082273304" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="1.581514548372864" LOG_CI_START="-0.18357453970082682" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12059529818843805" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5522797620005544">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="38.15175744716649" CI_START="0.6552778082273304" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.581514548372864" LOG_CI_START="-0.18357453970082682" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="207" O_E="0.0" SE="1.036822067666386" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="1.075" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.454355609940604" CI_START="0.7303709038490351" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.872410106924809" LOG_CI_START="-0.13645653633562027" LOG_EFFECT_SIZE="0.36797678529459443" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1527843988746297" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.4297652740176028">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.454355609940604" CI_START="0.7303709038490351" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.872410106924809" LOG_CI_START="-0.13645653633562027" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="208" O_E="0.0" SE="0.592613260221602" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.35119047619047616" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Major adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="209" O_E="0.0" SE="0.0" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.827010570207606" CI_START="0.19897343360788772" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.45132743232194045" LOG_CI_START="-0.7012049055385404" LOG_EFFECT_SIZE="-0.12493873660829995" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6708843647011454" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.42493458271336965">
<NAME>Sterile CSF culuture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.827010570207606" CI_START="0.19897343360788772" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.45132743232194045" LOG_CI_START="-0.7012049055385404" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="210" O_E="0.0" SE="0.67700320038633" STUDY_ID="STD-Brouwer-2004" TOTAL_1="16" TOTAL_2="16" VAR="0.45833333333333326" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Standard dose amphoteracin and flucytosine Vs high dose amphoteracin and flucytosine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.441232033277393" CI_START="0.041472370361144976" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.5367139569494853" LOG_CI_START="-1.382241141743625" LOG_EFFECT_SIZE="-0.4227635923970698" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.38780961843735395" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.8635964600082002">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.441232033277393" CI_START="0.041472370361144976" EFFECT_SIZE="0.37777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5367139569494853" LOG_CI_START="-1.382241141743625" LOG_EFFECT_SIZE="-0.4227635923970698" ORDER="211" O_E="0.0" SE="1.127203723953269" STUDY_ID="STD-Bicanic-2008" TOTAL_1="30" TOTAL_2="34" VAR="1.2705882352941176" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8749181650947926" CI_START="0.304474194212099" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7555555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.2729823167446082" LOG_CI_START="-0.5164495102107853" LOG_EFFECT_SIZE="-0.12173359673308856" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5455319914876109" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.6044688272211198">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8749181650947926" CI_START="0.304474194212099" EFFECT_SIZE="0.7555555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2729823167446082" LOG_CI_START="-0.5164495102107853" LOG_EFFECT_SIZE="-0.12173359673308856" ORDER="212" O_E="0.0" SE="0.463716162904165" STUDY_ID="STD-Bicanic-2008" TOTAL_1="30" TOTAL_2="34" VAR="0.2150326797385621" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.832851667370302" CI_START="0.028031607081162455" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.2631273189451682" LOG_CI_START="-1.5523520029720206" LOG_EFFECT_SIZE="-0.6446123420134261" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.16397465655978055" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="1.391827446431208">
<NAME>Major adverse event</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.832851667370302" CI_START="0.028031607081162455" EFFECT_SIZE="0.22666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2631273189451682" LOG_CI_START="-1.5523520029720206" LOG_EFFECT_SIZE="-0.6446123420134261" ORDER="213" O_E="0.0" SE="1.066421540461737" STUDY_ID="STD-Bicanic-2008" TOTAL_1="30" TOTAL_2="34" VAR="1.1372549019607843" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.938484652515351" CI_START="0.43180753790084786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1264367816091954" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.46812342676887925" LOG_CI_START="-0.36470978062112663" LOG_EFFECT_SIZE="0.051706823073876314" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8077184059917744" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.24337048542379816">
<NAME>Sterile CSF at 14 days</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.938484652515351" CI_START="0.43180753790084786" EFFECT_SIZE="1.1264367816091954" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.46812342676887925" LOG_CI_START="-0.36470978062112663" LOG_EFFECT_SIZE="0.051706823073876314" ORDER="214" O_E="0.0" SE="0.4892103486117543" STUDY_ID="STD-Bicanic-2008" TOTAL_1="29" TOTAL_2="28" VAR="0.23932676518883417" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Amphoteracin Vs liposomal amphoteracin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Death at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="215" O_E="0.0" SE="0.0" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="59.399212530180556" CI_START="0.11600532576924143" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="99.99999999999999" ID="CMP-011.02" LOG_CI_END="1.7737806874716955" LOG_CI_START="-0.935522071987744" LOG_EFFECT_SIZE="0.4191293077419757" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5442404722588213" Q="4.866650707885208E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.606413104014539">
<NAME>Death at 10 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="59.399212530180506" CI_START="0.11600532576924143" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773780687471695" LOG_CI_START="-0.935522071987744" LOG_EFFECT_SIZE="0.4191293077419757" ORDER="216" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.991596952010106" CI_START="0.1768194274458128" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="1.2302341978715983" LOG_CI_START="-0.7524700200413248" LOG_EFFECT_SIZE="0.23888208891513674" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6367236938618736" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.4722845562090043">
<NAME>Death at 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.991596952010106" CI_START="0.1768194274458128" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302341978715983" LOG_CI_START="-0.7524700200413248" LOG_EFFECT_SIZE="0.23888208891513674" ORDER="217" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="13" VAR="1.3564102564102565" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7356194128258255" CI_START="0.05042268607220497" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1925925925925926" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-0.13334681835200163" LOG_CI_START="-1.2973740226963746" LOG_EFFECT_SIZE="-0.7153604205241881" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.01599555300531095" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="2.4090169971285933">
<NAME>Major adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7356194128258255" CI_START="0.05042268607220497" EFFECT_SIZE="0.1925925925925926" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.13334681835200163" LOG_CI_START="-1.2973740226963746" LOG_EFFECT_SIZE="-0.7153604205241881" ORDER="218" O_E="0.0" SE="0.6837553418594751" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.4675213675213676" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="39.40765003281894" CI_START="0.9135282101322705" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="1.5955805376768575" LOG_CI_START="-0.03927803690957028" LOG_EFFECT_SIZE="0.7781512503836436" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.06207125958115181" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="9" WEIGHT="100.0" Z="1.86578637318836">
<NAME>Sterile CSF culture at 14 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="39.40765003281894" CI_START="0.9135282101322705" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.5955805376768575" LOG_CI_START="-0.03927803690957028" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="219" O_E="0.0" SE="0.960324019392529" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="9" VAR="0.9222222222222223" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.539519399906346E-31" CI_END="1.332503101239552" CI_START="0.670830932167536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9454545454545455" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="100.0" I2_Q="0.0" ID="CMP-011.06" LOG_CI_END="0.12466822846758338" LOG_CI_START="-0.1733869201864727" LOG_EFFECT_SIZE="-0.024359345859444645" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.7486905272296853" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.3203664877930414">
<NAME>Proportion of patients responding clinically after 3 weeks treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3325031012395518" CI_START="0.6708309321675359" EFFECT_SIZE="0.9454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.12466822846758331" LOG_CI_START="-0.17338692018647278" LOG_EFFECT_SIZE="-0.024359345859444693" ORDER="220" O_E="0.0" SE="0.17507906971617326" STUDY_ID="STD-Leenders-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.03065268065268066" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>